TY - JOUR
T1 - Extrahepatic manifestations associated with Chronic Hepatitis C Virus Infection
AU - Flores-Chávez, A.
AU - Carrión Rodríguez, José Antonio
AU - Forns, Xavier
AU - Ramos-Casals, M.
PY - 2017
Y1 - 2017
N2 - Chronic hepatitis C virus (HCV) infection has been associated with both organ-specific and systemic autoimmune diseases, with cryoglobulinemia being the most frequent associated disease. Experimental, virologic, and clinical evidence have demon-strated a close association between HCV infection and some systemic autoimmune diseases, especially Sjögren's syndrome, but also rheumatoid arthritis and lupus. A higher prevalence of hematological processes has also been described in patients with HCV infection, including cytopenias and lymphoproliferative disorders (B-cell lymphoma). In addition, patients with chronic HCV infection have a higher frequency of other extrahepatic manifestations including endocrine, metabolic and cardiovascular disorders that may worse the prognosis of patients, along with neuropsychiatric manifestations and general symptoms that have a significant influence on the quality of life of the patient. Direct-acting antiviral therapies (DAAs) that have recently begun to be used are providing the opportunity to effectively cure chronic HCV infection and reduce the burden of both hepatic and extrahepatic complications.
AB - Chronic hepatitis C virus (HCV) infection has been associated with both organ-specific and systemic autoimmune diseases, with cryoglobulinemia being the most frequent associated disease. Experimental, virologic, and clinical evidence have demon-strated a close association between HCV infection and some systemic autoimmune diseases, especially Sjögren's syndrome, but also rheumatoid arthritis and lupus. A higher prevalence of hematological processes has also been described in patients with HCV infection, including cytopenias and lymphoproliferative disorders (B-cell lymphoma). In addition, patients with chronic HCV infection have a higher frequency of other extrahepatic manifestations including endocrine, metabolic and cardiovascular disorders that may worse the prognosis of patients, along with neuropsychiatric manifestations and general symptoms that have a significant influence on the quality of life of the patient. Direct-acting antiviral therapies (DAAs) that have recently begun to be used are providing the opportunity to effectively cure chronic HCV infection and reduce the burden of both hepatic and extrahepatic complications.
KW - Prisons
KW - Hepacivirus
KW - Hepatitis C
KW - Antiviral agents
KW - Autoinmune diseases
KW - Lymphoma
KW - Spain
KW - Diabetes mellitus
UR - https://www.scopus.com/pages/publications/85073871613
M3 - Article
C2 - 29364334
SN - 2013-6463
VL - 19
SP - 87
EP - 97
JO - Revista Española de Sanidad Penitenciaria
JF - Revista Española de Sanidad Penitenciaria
ER -